Vor Bio Appoints Adi Osovsky, S.J.D., Strengthens Leadership With New General Counsel Appointment

Vor Bio is a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings more than 17 years of legal and compliance expertise in the biotechnology and pharmaceutical sectors, with extensive experience in corporate transactions, governance, and securities matters.

“We are delighted to welcome Adi to Vor Bio at this important stage in our growth. Adi’s proven experience advising public biopharmaceutical companies on governance, compliance, and strategic transactions makes her an outstanding addition to our leadership team. Her counsel will be invaluable as we advance our late-stage clinical programs and prepare for growth,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. 

Dr. Osovsky most recently served as Executive Vice President, Head of Legal & Corporate Secretary at iTeos Therapeutics, where she led the company’s corporate legal, compliance, and IT functions. She previously held senior legal roles at Sarepta Therapeutics, where she supported governance and corporate transactions during a period of significant expansion. Earlier in her career, she practiced in the Capital Markets group at Sullivan & Worcester LLP, advising life sciences companies on financing and regulatory issues.

“I am thrilled to join Vor Bio at such a pivotal time. Vor Bio’s mission to transform the treatment of autoimmune diseases deeply resonates with me, and I look forward to partnering with this talented team to advance the company’s mission and enable long-term success for patients,” said Dr. Osovsky. 

Dr. Osovsky holds an LL.B. from Tel Aviv University and earned both her LL.M. and S.J.D. in Securities Regulation from Harvard Law School. Her appointment strengthens Vor Bio’s leadership team as the company advances its clinical programs in autoimmune disease.